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ABSTRACT
Preparation of  SNEDDS aims to improve solubility and absorption of  furosemide in the body to reduce the dosage and minimize 
the side effects of  drugs. Ternary diagram constructed from composition mixture produced nanoemulsion in the range of  20-40% of  
capryol-90, 20-40% polysorbate-80 and 40-60% PEG-400. Formulations of  SNEDDS using Design-Expert®10 with simplex-lattice-de-
sign method in the study was aimed to investigate the effect of  SNEDDS each component’s proportions towards test responses. Emulsifi-
cation time, drug content and viscosity were best demonstrated by run-7 with consecutive values of  131.68±2.14 seconds, 99.89±2.68% 
and 0.87±0.0043 mm2/s. The optimum formula was obtained through entering test response parameter data of  all thirteen formula. 
Drug content and emulsification time was 107.0 ± 1.44% and 155.59±1.56 seconds with viscosity value 0.91±0.00 mm2/s. From the 
physical stability studies, SNEDDS formulas were stable and did not show phase separation when exposed to temparature stress testing. 
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1. INTRODUCTION
Diuretics are edema therapy used due to heart failure, renal fail-
ure, and high blood pressure-lowering therapy. Diuretics meshes 
Henle, such as furosemide, bumetanide, and torsemid are diuretic 
commonly used in the treatment of  heart failure. Furosemide has 
been formulated in various dosage preparations including tablets 
and injection dosage. Absorption from oral use of  furosemide er-
ratic ranging between 11-90% depends on the formulation and 
effectiveness (Chungi et al., 1979; Akbuga et al., 1988; Jackson, 
2006). 
According to Ozdmir and Ordu (1998) furosemide is clasified 
into the biopharmaceutical classification system (BCS) Group IV 
that has a problem in solubility and low permeability. Nanopar-
ticulate form of  self-emulsifying drug delivery system (SNEDDS) 
furosemide is expected to resolve the issue of  its low solubility. 
SNEDDS is an isotropic mixtures of  oil, surfactant, co-surfactant 
and drug in a dosage of  nanoemulsion oil in water (o/w). SNEDDS 
nanoemulsion is formed due to the mild agitation motility of  the 
gastrointestinal tract (Hiral et al., 2013). Furosemide is dissolved 
in the oil phase into the gastrointestinal tract that contains the 
water phase, nanoemulsion droplet is formed and come in contact 
with the gastric mucosal membrane. Droplet will release furosem-
ide and be absorbed into the blood vessels surrounding mucosa 
thus improving the bioavailability of  furosemide (Jyoti et al., 2012; 
Balakumar et al., 2013).
SNEDDS constituent component of  the manufacturing pro-
cess comprise of: an oil phase in the form of  capryol-90 a mono-
glycerides compound that has the ability to dissolve lipophilic 
drugs well, polysorbate (tween) 80 as a surfactant because of  its 
high emulsifying properties and can increase the permeability of  
furosemide and polyethylene glycol (PEG) 400 as a co-surfactant 
to increase the loading dose, accelerate emulsification, and mini-
mize droplet size (Anton and Vandamme, 2009; Rowe et al., 2009; 
Kumar and Rajeshwarrao, 2011; Wulandari, 2013). 
The simplex lattice design (SLD) was employed during for-
mula optimization to observe effect of  main components concen-
tration variation towards furosemide SNEDDS physicochemical 
characteristics (Bolton, 1997). Software DX®10 used was able to 
facilitate data analysis and determine the most optimum composi-
tion ratio with minimal number of  experiments compared to trial 
and error.
2. EXPERIMENTAL SECTION
2.1. Materials and Equipments
Furosemide was kindly gifted by PT. Ifars Pharmaceutical Labora-
tories. Capryol-90 was purchased from Gattefose. The other ma-
terials used in this study are pharmaceutical and analytical grade 
products supplied by Merck such as PEG-400, polysorbate-80 fil-
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ter Whatmann size 0.22 μm, KH2PO4, and NaOH pellets.
Equipments used in this research are laboratory staple 
equipments and spectrophotometer UV to evaluate furosemide 
SNEDDS drug content.
2.2. Furosemide solubility testing in Capryol-90
The maximum solubility of  furosemide (mg) in capryol-90 was 
measured by the method of  trial and error. Pure furosemide was 
weighed as much as 1, 2, 3, 4, and 5 mg and dissolved respectively 
in 0.5 mL capryol-90. The mixture was stirred for 15 minutes at 
a speed of  240 rpm. The highest concentrations (mg) to dissolve 
furosemide in 0.5 mL capryol-90 is recorded as the highest con-
centration that will be used in the formulation process.
2.3. Construction of  the Ternary Diagram
Ternary diagram was made by mixing each component of  
SNEDDS furosemide (capryol-90, polysorbate-80, and PEG-400) 
in different proportions according to the diagram. Testing of  na-
noemulsion region was conducted by mixing a solution of  40 mL 
capryol-90, polysorbate-80, and PEG-400 in 25 mL of  distilled 
water and stirred at 100 rpm (Soni et al., 2014). Evaluation of  
results was done organoleptically by its dispersibility and colour.
2.4. Formula Determination with Simplex-Lattice-De 
sign (SLD)
Determining the composition of  formula was done by the sim-
plex-lattice-design. Low and high value of  each component was 
determined based on the ternary diagram result. Order used in 
the SLD method is quadratic with three times formula replication 
to obtain 13 formulas tested.
2.5. SNEDDS Furosemide Preparation
Furosemide put in each formula was each tailored to preliminary 
test results of  solubility and put in a glass beaker. The oil phase 
(capryol-90 ) was stirred with a hot plate stirrer for 15 minutes and 
sonicated for 45 minutes. PEG-400 is inserted into the solution 
above, while the solution is constantly stirred for 15 minutes with 
a hot plate stirrer. In the next stage, the mixture is sonicated and 
mixed with polysorbate-80 dropwise using a micro pipette into 
the glass beaker. The mixture was sonicated for 45 minutes until it 
becomes a light yellow clear solution. The amount of  each com-
position for the formula can be seen in Table 1.
2.6. Drug Content Test
The quantity of  furosemide contained in SNEDDS preparation 
was measured by mixing 25 mL of  the solution with 5 mL meth-
anol for analysis. Absorbance of  the mixture was measured by 
UV-Vis spectrophotometer at a wavelength of  275 nm (Yadav et 
al.. 2014).
2.7. SNEDDS pH Test
Furosemide was checked for pH level to determine whether it sta-
ble in the pH range of  4-9 (Kenneth et al., 1986). pH strip indica-
tors were used in the pH test. 
2.8. Viscosity Test
SNEDDS furosemide viscosity testing is done by diluting SNEDDS 
furosemide at a1: 100 scale with distilled water and then put into 
Oswald viscometer. Take note of  the time required by the solution 
to cross the first line and the second line.
2.9. Emulsification Time Test
Nanoemulsion formation time was determined by dropping every 
20 mL of  each formula in 12.5 mL of  distilled water and stirred 
100 rpm at room temperature. Record the time required to make 
the mixture becomes clear (Soni et al.. 2014).
2.10. Physical Stability Test
Physical stability of  the SNEDDS formula is tested by heat-
ing-cooling method performed on the formula for three cycles. 
Viscosity changes. deposition of  furosemide. and clarity of  solu-
tion were observed in each cycle. A cycle is a combination of  0ºC 
temperature for 1x24 hour and a temperature of  40°C for 1x24 
hours (Kaur et al.. 2013). 
3. RESULTS AND DISCUSSION
Furosemide solubility testing aims to determine how much a 
Table 1.  SNEDDS furosemide formulation composition with 
SLD method
For-
mula
Component
Furosemide 
(mg)
Capryol-90 
(mL)
Polysor-
bate-80 
(mL)
PEG-400 
(mL)
Run 1 16 33,33 23,33 43,33
Run 2 16 40 20 40
Run 3 16 20 20 60
Run 4 16 23,33 23,33 53,33
Run 5 16 30 30 40
Run 6 16 23,33 33,33 43,33
Run 7 16 20 40 40
Run 8 16 20 30 50
Run 9 16 26,67 26,67 46,67
Run 10 16 40 20 40
Run 11 16 30 20 50
Run 12 16 20 20 60
Run 13 16 20 40 40
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capryol-90 (mL) can dissolve furosemide (mg). The results ob-
tained from this preliminary test is 8 mg of  furosemide which can 
be dissolved in 1 mL capryol-90 and was used as a reference to 
the addition of  the furosemide active substance to the SNEDDS 
solution formulation
The construction the ternary diagram was intended to deter-
mine nanoemulsion area that can be formed with a mixture of  
components capryol-90, polysorbate-80, and PEG-400. Obser-
vation result of  the nanoemulsion region produced can be seen 
in Figure 1. Nanoemulsion area indicated by the shading colored 
green or yellow is marked by a clear colloidal white milk solution 
(droplet of  oil is not visible), while the area in gray is an area that 
contained the separation phase of  oil and water or produces oil 
globules that were still visible to the eye. Capryol-90 in the range 
of  20-40%, polysorbate-80 20-80% and PEG-400 0-80% were 
found to produce the nanoemulsion mixture.
 The use of  stirrer in the preparation was intended to 
mix all substances evenly in capryol-90 with a constant speed and 
power. Sonication process aims to homogenize and shrink the size 
of  furosemide which had not been dissolved after the stirrer. The 
solution of  the SNEDDS furosemide produced for all 13 formulas 
with different proportions of  components is in the form of  clear 
yellow solution.
Results of  the drug content thirteen formula testing still qual-
ifies the USP requirements range (80-120%) as shown in Table 
2. Formula 7 is a formula with the biggest drug response value 
among other formulas with ANOVA test analysis showing no sig-
nificant differences between the formula with a p-value (> 0.05).  
The equation obtained after entering the drug content re-
sponse value into DX®10 program is as follows:
Y = 94,35 A + 97,42 B + 91,72 C - 19,99 AB - 11,53 AC – 3,75 
BC + 607,64 A2BC + 160,66 AB2C – 654,05 ABC2
From the equation polysorbate-80 concentration (B) had a bigger 
contribution towards drug content compared to capryol-90 (A) 
and PEG-400 (C).
PH test results from the 13 SNEDDS formulas can be seen 
in Table 2. The pH of    SNEDDS was measured using a pH 
indicator showing results between pH value of  5 - 6. Capryol-90 
pH is between 4.0 to 6.0, while the pH of  PEG-400 (5% w/v) is 
4.0 to 7.0 and polysorbate-80 having a pH of  6.0 to 8.0 (Rowe et 
al.. 2009). Pure furosemide is stable in the pH 4-9 so SNEDDS 
preparations are made to maintain the stability of  the active sub-
stance in the absence of  hydrolysis-mediated due to excessive acid 
or alkaline (Kenneth et al.. 1986).
Viscosity can affect the stability of  liquid solution. The high-
er the viscosity of  the preparation, the more stable the substanc-
es that are in it because there is less tendency of  the particles to 
collide with each other. Viscosity data from the 13 formulas of  
SNEDDS furosemide can be seen in Table 2 with the analysis of  
ANOVA p-value (<0.05). which means there is a significant dif-
ference among the SNEDDS formula. Formula 7 has the highest 
viscosity among the thirteen other formulas. The equation that 
states the relationship of  response and proportion of  constituent 
components SNEDDS furosemide is as follows:
Y = 0.82 A + 0.88 B + 0.85 C
Polysorbate-80 (B) accounts for higher viscosity level com-
pared to capryol-90 (A) or PEG-400 (C) due to the viscosity of  
polysorbate-80, which is bigger than the other components. 
SNEDDS solution emulsification time observation was per-
formed to determine how quickly it would form an emulsion of  
nanometer-size when it is inside the body. The faster the solution 
turns into nanometer-sized oil droplet. the faster the drug can 
be dissolved and be absorbed into the blood vessels (Hiral et al.. 
2013). Emulsification time test results are shown in Table 2. The 
best emulsification time value is shown by formula 7 and 13 which 
are replication formula. Emulsification time response on the pro-
portion of  each component can be seen in the following equation:
Y = 903.28 A + 134.32 B + 564.35 C + 1577.26 AB + 717 AC 
– 253.5 BC – 16785.81 A2BC + 33474 AB2C – 630 ABC2
ANOVA tests of  thirteen formula produces a p-value of  (<0.05), 
which means that there are significant differences in each formula.
SNEDDS furosemide turned into solid  form (frozen) 
when placed in 0ºC  temperature, with yellowish muddy color. 
SNEDDS frozen state when left to sit at room temperature within 
minutes transformed back into liquid formwith the same physical 
appearance as before it is inserted into the freezing temperature. 
Temperature can affect the activation energy of  a molecule drugs. 
the greater the activation energy then the drug will be slower to 
decompose (Anderson and Scott, 1991). This result showed that 
temperature can affect the physical appearance of  SNEDDS but 
it did not affect the emulsified state of  dosage form.
Table 2. SNEDDS Furosemide 13 Formulas Response Test Results
Formula Drug Content (%) ± SD Emulsification Time 
(second) ± SD
Viscosity Response 
(mm2/s) ± SD pH Physical Stability
1 97.774 ± 4.093 900.00 ± 0.00 0.8291 ± 0.0007 5 – 6 Stable
2 92.937 ± 0.817 900.00 ± 0.00 0.8101 ± 0.0027 5 – 6 Stable
3 91.531 ± 1.326 568.50 ± 4.50 0.8474 ± 0.0021 5 – 6 Stable
4 86.128 ± 2.096 727.56 ± 5.29 0.8402 ± 0.0074 5 – 6 Stable
5 90.564 ± 3.150 900.00 ± 0.00 0.8410 ± 0.0039 5 – 6 Stable
6 95.818 ± 0.327 900.00 ± 0.00 0.8561 ± 0.0033 5 – 6 Stable
7 99.899 ± 2.681 131.68 ± 2.14 0.8767 ± 0.0043 5 – 6 Stable
8 93.306 ± 1.810 272.84 ± 1.81 0.8743 ± 0.0024 5 – 6 Stable
9 90.523 ± 0.791 900.00 ± 0.00 0.8696 ± 0.0063 5 – 6 Stable
10 95.604 ± 2.705 900.00 ± 0.00 0.8252 ± 0.0014 5 – 6 Stable
11 89.825 ± 2.136 900.00 ± 0.00 0.8280 ± 0.0022 5 – 6 Stable
12 91.742 ± 0.610 553.63 ± 3.30 0.8433 ± 0.0008 5 – 6 Stable
13 94.777 ± 1.908 130.39 ± 2.13 0.8727 ± 0.0061 5 – 6 Stable
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CONCLUSION
SNEDDS of  furosemide can be prepared using the mixture of  
capryol-90, polysorbate-80 and PEG-400 with favorable results. 
The proportion of  capryol-90, polysorbate-80, and PEG-400 in 
forming nanoemulsion regions are 20-40%, 20-40% and 40-60%. 
Capryol-90 in the mix will increase emulsification time, in contrast 
to the proportion of  polysorbate-80 which if  added will reduce 
the time of  emulsification and increase viscosity. Drug content re-
sponse was not influenced by differences in the composition of  
SNEDDS.
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